AECOM Slashes FY Outlook to $4.05, Triggering Shareholder Probe and Thesis Downgrade

What happened

AECOM announced a full-year adjusted EPS outlook of roughly $4.05 at the midpoint, far below market expectations near $5.97, representing a 32% shortfall. This comes after the company had previously guided FY2026 adjusted EPS to $5.65–$5.85, indicating a severe deterioration in expected profitability. The disappointing guidance prompted SueWallSt to notify investors of potential securities claims, though the article itself is a law firm solicitation and should be viewed with skepticism. The DeepValue master report had rated ACM as WAIT due to rich valuation (~40% above FCF-based DCF) and concerns about cyclicality and legacy liabilities; this guidance cut appears to validate those risks. The stock is likely to face negative repricing as investors reassess the company's earnings power and growth trajectory.

Implication

The prior investment thesis assumed high-single-digit EPS growth and robust FCF conversion, but the new guidance implies a significant reset, possibly due to weaker demand, project delays, or unexpected charges. Given the stock's premium valuation (23x trailing P/E, ~11.6x EV/EBITDA) and no margin of safety relative to DCF, the risk-reward is now unfavorable. The shareholder investigation adds litigation overhang and potential reputational damage, though its merits are uncertain. Investors should monitor for further guidance updates, backlog trends, and any evidence of structural deterioration versus transitory issues. Until management provides a credible explanation and recovery path, avoiding the stock or selling into rallies appears prudent.

Thesis delta

The prior WAIT stance was based on rich valuation and balanced risk; the new guidance of $4.05 vs. $5.97 consensus represents a material negative shock, indicating that underlying business conditions have deteriorated beyond what was priced in. This shifts the thesis to SELL or at least a strong caution, as the earnings power has reset lower and litigation risk adds downside.